Table 3.

Change from baseline in ADAS-Cog total scores at week 24 – MMRM¹ (ITT population)

Subject group	Treatment group	Number2	LSM	SE	Treatment comparison
					difference3	95% CI	P
APOE ε4 negative	placebo	63	1.6	0.78	_	_	_
	2 mg RSG XR	69	−0.2	0.67	−1.8	−3.8,0.2	0.074
	8 mg RSG XR	65	0.6	0.67	−1.0	−3.0, 1.0	0.338
	10 mg donepezil	28	0.9	1.16	−0.7	−3.5,2.1	0.6024
All except ε4/ε4	placebo	117	1.5	0.58	-	-	-
	2 mg RSG XR	115	0.3	0.54	−1.2	−2.7, 0.4	0.131
	8 mg RSG XR	112	0.7	0.57	−0.8	−2.4, 0.8	0.315
	10 mg donepezil	49	−0.1	0.79	−1.6	−3.5,0.3	0.1054
Full population	placebo	131	2.0	0.56	-	-	-
	2 mg RSG XR	130	1.2	0.53	−0.8	−2.2, 0.6	0.272
	8 mg RSG XR	125	1.2	0.55	−0.8	−2.2, 0.7	0.297
	10 mg donepezil	56	0.6	0.74	−1.3	−3.1,0.4	0.1314

ADAS-Cog total scores range from 0 to 70, with negative change from baseline indicating clinical improvement. LSM = Least squares mean; SE = standard error for LSM.

¹Model includes terms for country group, visit, APOE ε4 gene dose, treatment, baseline body mass index, baseline MMSE score, baseline MMSE score by visit, and treatment by visit

²Number of subjects with an ADAS-Cog score at week 24.

³Difference (active treatment minus placebo).

⁴Unadjusted p.